Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) headquartered in Washington, will host a conference call for the investment community to discuss the 3Q20 financial results on 28th October 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.vandapharmaceuticals.com
Earnings Expectation
Vanda Pharmaceuticals Inc. is set to announce third quarter earning results on Wednesday 28th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, VNDA to report 3Q20 income of $ 0.09 per share. For the full year, analysts anticipate top line of $ 251.05 million, while looking forward to income of $ 0.37 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 240.00 million ~ $ 260.00 million
Click Here For More Historical Outlooks Of Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The companys marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in clinical development stage for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
